Additionally, gene-editing technologies, such as CRISPR-Cas9, are being harnessed to precisely regulate the cGAS-STING pathway, aiming to enhance the specificity and efficacy of anti-tumor immune responses 71, 72. The gene discussed is STING1; the disease is neoplasm.